Conference Coverage

Atopic dermatitis: Pivotal dupilumab results create sensation

Publish date: October 6, 2016

 

Pages

Recommended Reading

Phase III dupilumab data show significant improvements in atopic dermatitis
MDedge Internal Medicine
Cochrane Review nixes specific allergen immunotherapy for atopic dermatitis
MDedge Internal Medicine
New treatments bring hope for severe atopic dermatitis
MDedge Internal Medicine
Sublingual immunotherapy for allergy-related asthma
MDedge Internal Medicine
Atopic dermatitis increases risk of ADHD, comorbidities add to it
MDedge Internal Medicine
Crisaborole’s safety holds up in long-term atopic dermatitis trial
MDedge Internal Medicine
Skin patch testing pinpoints dietary triggers of IBS
MDedge Internal Medicine
Ustekinumab misses primary endpoint in atopic dermatitis
MDedge Internal Medicine
Drugs in the pipeline hold promise for atopic dermatitis
MDedge Internal Medicine
EpiPen cost increases far exceed overall medical inflation
MDedge Internal Medicine

Related Articles